|
|
 Previous Article | Table of Contents | Next Article 
Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of
prestorage filtered platelets and red blood cells: a prospective study [see
comments]
VM Novotny, R van Doorn, MD Witvliet, FH Claas and A Brand
Red Cross Blood Bank Leiden, The Netherlands.
The incidence and consequences of HLA and non-HLA immunization were
evaluated in 229 patients with aplastic thrombocytopenia. All patients were
transfused with prestorage filtered red blood cells and platelets. On
admission, 29 patients presented with HLA antibodies due to prior
immunization by pregnancy and/or blood transfusions. Of the 200 patients
showing no detectable HLA antibodies on admission, 164 could be evaluated.
HLA antibodies developed in 2.7% (3 of 112) of the patients with a negative
risk history of prior immunization. The occurrence of HLA antibodies in
patients with a history of previous pregnancies or prior
non-leukocyte-depleted blood transfusions (risk history positive) was 31%
(16 of 52). Of the total of 48 patients who were or became alloimmunized,
92% (44 of 48) had a positive risk history. Ten patients with broad
multispecific HLA antibodies with a panel reactivity (PRA) of greater than
70% required transfusions with HLA-matched platelets. Patients with HLA
antibodies with lower PRA could be supported by random donor platelets. Two
patients developed platelet-specific antibodies, causing transfusion
refractoriness that necessitated selecting platelets by the absence of a
platelet-specific antigen. Using prestorage leukocyte depletion of red
cells and platelets with less than 5 x 10(6) residual leukocytes, 95% of
the patients, including patients with a previous risk history or with HLA
antibodies with low PRA, can be supported with random donor transfusions
for the entire duration of their thrombocytopenic periods.
Volume 85,
Issue 7,
pp. 1736-1741,
04/01/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. J. Slichter, D. Fish, V. K. Abrams, L. Gaur, K. Nelson, and D. Bolgiano
Evaluation of different methods of leukoreduction of donor platelets to prevent alloimmune platelet refractoriness and induce tolerance in a canine transfusion model
Blood,
January 15, 2005;
105(2):
847 - 854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Seftel, G. H. Growe, T. Petraszko, W. B. Benny, A. Le, C.-Y. Lee, J. J. Spinelli, H. J. Sutherland, P. Tsang, and D. E. Hogge
Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness
Blood,
January 1, 2004;
103(1):
333 - 339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Schiffer, K. C. Anderson, C. L. Bennett, S. Bernstein, L. S. Elting, M. Goldsmith, M. Goldstein, H. Hume, J. J. McCullough, R. E. McIntyre, et al.
Platelet Transfusion for Patients With Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology
J. Clin. Oncol.,
March 1, 2001;
19(5):
1519 - 1538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gouttefangeas, M. Diehl, W. Keilholz, R. F. Hornlein, S. Stevanovic, and H.-G. Rammensee
Thrombocyte HLA molecules retain nonrenewable endogenous peptides of megakaryocyte lineage and do not stimulate direct allocytotoxicity in vitro
Blood,
May 15, 2000;
95(10):
3168 - 3175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Kruskall
The Perils of Platelet Transfusions
N. Engl. J. Med.,
December 25, 1997;
337(26):
1914 - 1915.
[Full Text]
|
|
|
|
|
